Photo Alamy
President Trump revealed a new plan to impose tariffs on foreign pharmaceuticals Tuesday night while speaking at the National Republican Congressional Committee Dinner.
He stated, “We’re gonna tariff our pharmaceuticals, and once we do that they’re gonna come rushing back into our country because we’re the big market.”
The 47th president predicted that these tariffs would force pharmaceutical companies to leave China and other nations that have issued numerous recalls for drug safety concerns, which adversely affected Americans.
According to the National Library of Medicine, between 1999 and 2021, Chinese-made pharmaceuticals resulted in more than one safety recall per year.
In 2018, corporate media outlets like NBC reported on the dangers of China controlling most of the American medicine supply after the blood pressure drug valsartan was contaminated with the cancer-causing chemical NDMA.
By 2019, Bloomberg was reporting on the lack of proper FDA oversight regarding Chinese drugs.
In 2022, Pfizer chose to utilize the Chinese Zhejiang Huahai Pharmaceutical Co. to manufacture an oral COVID-19 Paxlovid pill despite this drug manufacturer previously issuing a recall on an oral COVID antiviral due to tainted ingredients, per the Seattle Times.
The next year, even Chinese herbal medicines were recalled in China after poisonous pesticides that cause nervous system issues related to prolonged use were found in the ingredients, via the Chinese Medicine Regulatory Office.
Indian pharmaceutical companies are no strangers to safety recalls either. The Coalition for a Prosperous America (CPA) reported that four major Indian drug manufacturers issued product recalls in 2025 alone.
According to ProPublica, one of these manufacturers was Glenmark Pharmaceuticals, which manufactured 50 million potassium chloride extended-release capsules that the FDA determined had the capacity to kill U.S. patients.
What’s more, The Heritage Foundation reported that China and India, “Have both historic and recent histories of poor quality control, on top of egregious instances of pharmaceutical fraud.”
Despite this, “According to official FDA records and publications, the FDA doesn’t independently collect and test >99.9% of drugs from overseas, including China and India.”
While President Trump has received criticism for his recent tariff policies, the pharmaceutical industry continues manufacturing American medicine overseas in nations that have continued to produce safety issues with little oversight from the FDA before dispensing said medications to the American public.